WCG has acquired life-sciences consulting firm, The Avoca Group, to expand its portfolio of solutions for enhancing clinical trial quality management and compliance transformation.
Focused on advancing efficiency, boosting process quality and alleviating risk in clinical trials, Avoca supports biopharma, biotech, CRO and clinical service providers.
The deal is expected to bolster WCG’s leadership in benchmarking and analytics of clinical trials along with the capabilities of already acquired companies, KMR Group and Metrics Champion Consortium.
This will potentially position WCG as a global leader to drive quality management best practices and compliance throughout the clinical trials industries.
WCG chairman and CEO Donald Deieso said: “Combined with the mounting pressures on the biopharmaceutical industry to increase development success rates while bringing new products to market faster, we have reached a tipping point where quality management and quality by design will assume unprecedented levels of importance to patient communities, regulators, and healthcare stakeholders.
“The Avoca Group brings exceptionally strong leadership to WCG and the respect and engagement of top-tier biopharmaceutical companies, CROs and clinical research sites in their work of establishing clinical trial best practices.”
WCG works on enhancing patient access to required treatments by cutting down the time needed, and costs incurred in conducting clinical trials, guaranteeing regulatory compliance as well as better quality management.
The Avoca Group founder and CEO Patricia Leuchten said: “Our mission aligns with the mission of WCG as a transformative and unifying force for increasing the quality and compliance of clinical trials, assuring that medicines can reach patients faster and reliably.”
With the acquisition, The Avoca Group will become WCG Avoca while continuing its management structure and its headquarters in Princeton, NJ, in the US.